{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:41Z","timestamp":1792404041859,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jpba.2017.07.040","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T23:15:59Z","timestamp":1501974959000},"page":"718-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A simple high performance liquid chromatography\u2013mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples"],"prefix":"10.1016","volume":"145","author":[{"given":"Giovanna","family":"Fatiguso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Favata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Zedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Avataneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.07.040_bib0005","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4103\/0972-5229.194007","article-title":"Risk factors for early invasive fungal disease in critically ill patients","volume":"20","author":"Singh","year":"2016","journal-title":"Indian J. Crit. Care Med."},{"key":"10.1016\/j.jpba.2017.07.040_bib0010","first-page":"195","article-title":"Opportunistic invasive fungal infections: diagnosis & clinical management","volume":"139","author":"Badiee","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.jpba.2017.07.040_bib0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/2141-9248.113669","article-title":"Fungal infections in intensive care unit: challenges in diagnosis and management","volume":"3","author":"Bajwa","year":"2013","journal-title":"Ann. Med. Health Sci. Res."},{"key":"10.1016\/j.jpba.2017.07.040_bib0020","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/jac\/dkv177","article-title":"High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients","volume":"70","author":"Fuhren","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/AAC.02234-15","article-title":"Azole resistance in aspergillus fumigatus clinical isolates from an italian culture collection","volume":"60","author":"Lazzarini","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0030","doi-asserted-by":"crossref","first-page":"26213","DOI":"10.1038\/srep26213","article-title":"Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14alpha-demethylase","volume":"6","author":"Sagatova","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2017.07.040_bib0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.jpba.2017.07.040_bib0040","first-page":"869","article-title":"Molecular properties impact on bioavailability of second generation triazoles antifungal agents","volume":"70","author":"Grudzien","year":"2013","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.jpba.2017.07.040_bib0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00277-013-1693-5","article-title":"Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis","volume":"92","author":"Ping","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jpba.2017.07.040_bib0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/2047-783X-16-4-139","article-title":"Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature","volume":"16","author":"Sandherr","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.jpba.2017.07.040_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpba.2017.07.040_bib0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.jpba.2017.07.040_bib0065","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2017.07.040_bib0070","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug\u2013drug interaction associated with mold-Active triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/1389200215666141125121511","article-title":"Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450","volume":"15","author":"Niwa","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2017.07.040_bib0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12281-015-0224-3","article-title":"Fundament and prerequisites for the application of an antifungal TDM service","volume":"9","author":"Bruggemann","year":"2015","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.jpba.2017.07.040_bib0085","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0090","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/phar.1533","article-title":"Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole","volume":"35","author":"Guarascio","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2017.07.040_bib0100","series-title":"Guidance for Industry Bioanalytical Method Validation","author":"FDA","year":"2013"},{"key":"10.1016\/j.jpba.2017.07.040_bib0105","series-title":"Guideline on Bioanalytical Method Validation","author":"EMA","year":"2012"},{"key":"10.1016\/j.jpba.2017.07.040_bib0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2017.07.040_bib0115","doi-asserted-by":"crossref","DOI":"10.4155\/bio-2017-0059","article-title":"Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect","author":"De Nicol\u00f2","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2017.07.040_bib0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jms.3909","article-title":"First UHPLC-MS\/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients","volume":"52","author":"Pensi","year":"2017","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2017.07.040_bib0125","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.01807-09","article-title":"Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma","volume":"54","author":"Baietto","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0130","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jpba.2009.06.030","article-title":"Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection","volume":"50","author":"Gordien","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.040_bib0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2016.03.039","article-title":"Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry","volume":"1020","author":"Liang","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.040_bib0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2012.01.015","article-title":"Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection","volume":"887\u2013888","author":"Wissen","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.040_bib0145","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/FTD.0b013e3181b20b40","article-title":"A rapid and sensitive LC-MS\/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections","volume":"31","author":"Wu","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2017.07.040_bib0150","first-page":"1","article-title":"Novel antifungal agents: a patentreview (2013\u2013present)","author":"Castelli","year":"2016","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.jpba.2017.07.040_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2017.01.007","article-title":"Therapeutic drug monitoring\u2014key to personalized pharmacotherapy","author":"Oellerich","year":"2017","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2017.07.040_bib0160","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1093\/jac\/dkw408","article-title":"Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy","volume":"71","author":"Reeves","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl. 4","key":"10.1016\/j.jpba.2017.07.040_bib0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.761135","article-title":"Optimizing antifungal choice and administration","volume":"29","author":"Andes","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpba.2017.07.040_bib0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.jpba.2017.07.040_bib0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jcph.798","article-title":"CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects","volume":"57","author":"Zhu","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2017.07.040_bib0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.07.040_bib0185","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2017.07.040_bib0190","first-page":"227","article-title":"Determination of fluconazole in human plasma by reverse phase high performance liquid chromatography","volume":"72","author":"Safaei","year":"2015","journal-title":"Acta Pol. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851730986X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851730986X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T20:52:46Z","timestamp":1659300766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851730986X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":38,"alternative-id":["S073170851730986X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.07.040","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simple high performance liquid chromatography\u2013mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}